g logo ipb green

Overview

The following summary of the Primary Care Women's Health Forum's Menopause—guidance on management and prescribing HRT for GPs, is based on nice Guideline 23, Menopause: diagnosis and management.

For the full set of recommendations, refer to the full guideline.

Diagnosis

  • Diagnosis can be made without laboratory tests in otherwise healthy women aged over 45 years with appropriate symptoms:
    • perimenopause based on vasomotor symptoms and irregular periods
    • menopause in women who have:
      • not had a period for at least 12 months and are not using hormonal contraception or
      • symptoms in women without a uterus
  • Consider using a follicle-stimulating hormone (FSH) test to diagnose menopause only:
    • in women aged 40–45 years with possible menopausal symptoms, including a change in their menstrual cycle
    • in women aged under 40 years in whom menopause is suspected
  • If possible, test day 2–5 of the cycle
  • Two FSH levels over 30 mIU/ml taken 6 weeks apart in women using hormonal contraception rendering them amenorrhoeic (intrauterine system, progestogen-only pill, etonogestrel implant), can be used to determine when contraception can be stopped (after a further 1 year in women over 50 years, 2 years in those under 50 years)
  • Some women may have normal levels of FSH during the menopausal transition, so this should not exclude perimenopause as a cause of their symptoms.

Vasomotor symptoms

  • Offer women hormone replacement therapy (HRT) after discussing with them the short-term (up to 5 years) and longer-term benefits and risks
  • Offer a choice of preparations as follows:
    • oestrogen and progestogen to women with a uterus
    • oestrogen alone to women without a uterus
  • Do not offer selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, or clonidine as first-line treatment for vasomotor symptoms alone
  • Consider testosterone supplementation for menopausal women with low sexual desire if HRT alone is not sufficient.

Genitourinary syndrome of menopause

  • Vaginal oestrogen can be given to women with urogenital atrophy (including those on systemic HRT) and continued for as long as needed to relieve symptoms. Treatment should be started early before irreversible changes have occurred
  • If vaginal oestrogen does not relieve symptoms of urogenital atrophy, consider increasing the dose beyond the licensed twice-weekly dose after seeking advice from a healthcare professional with expertise in menopause. Vaginal moisturisers and lubricants can be used alone or in addition to vaginal oestrogen
  • There is no need for monitoring of endometrial thickness during treatment of urogenital atrophy with vaginal oestrogens. However, advise women they should report unscheduled vaginal bleeding promptly.

Venous thromboembolism

  • The risk of venous thromboembolism (VTE) is increased by oral HRT compared with baseline population risk (relative risk=2)
  • The risk of VTE associated with HRT is more significant for oral than transdermal preparations
  • The risk associated with transdermal HRT given at standard therapeutic doses (under 50 mcg/24 hours) is no greater than the baseline population risk
  • Consider transdermal rather than oral HRT for menopausal women who are at increased risk of VTE, including those with a body mass index over 30 kg/m2
  • Consider referring menopausal women at high risk of VTE (e.g. those with a strong family history of VTE or a hereditary thrombophilia) to a haematologist or local specialist/GP with special interest in the menopause for assessment, before considering HRT.

Cardiovascular disease

  • HRT does not increase coronary heart disease risk when started in women aged under 60 years, and does not affect the risk of dying from cardiovascular disease
  • The presence of cardiovascular risk factors is not a contraindication to HRT as long as they are optimally managed
  • The baseline risk of coronary heart disease and stroke for women around menopausal age varies according to their personal cardiovascular risk factors
  • HRT with oestrogen alone is associated with no, or reduced, risk of coronary heart disease
  • HRT with oestrogen and progestogen is associated with little or no increase in the risk of coronary heart disease
  • Taking oral oestrogen (but not transdermal under 50 mcg/24 hours) is associated with a small increase in the risk of stroke, but the baseline population risk of stroke in women aged under 60 years is very low, so the increased risk is non significant.

Type 2 diabetes 

  • Taking HRT (either orally or transdermally) is not associated with an increased risk of developing type 2 diabetes
  • In women with diabetes, HRT is not generally associated with an adverse effect on blood glucose control.

Osteoporosis

  • Give women advice on bone health and discuss any risk factors for osteoporosis
  • The baseline population risk of fragility fracture for women around menopausal age in the UK is low and varies according to their personal and familial risk factors
  • Risk of fragility fracture is decreased while taking HRT but increases once treatment stops, although benefits may persist for a while in women who take HRT for longer
  • HRT is the only treatment that gives protection against all fractures, even in women with normal bone density
  • Women who have undergone an early menopause, either natural or surgical, should be prescribed HRT and advised to continue until at least the normal age of the menopause. Women with established osteoporosis aged under 60 years, especially with menopausal symptoms, should be given HRT to improve their bone density.

Loss of muscle mass and strength

  • There is limited evidence suggesting that HRT may maintain muscle mass and strength, which otherwise tends to decrease after the menopause. Muscle mass and strength is also maintained through daily activities and weight-bearing exercise.

Breast cancer

  • The baseline risk of breast cancer for women around menopausal age varies according to the presence of underlying familial and environmental risk factors
  • There is still no evidence of any increase in mortality from breast cancer in women taking HRT. NICE stated that:
    • HRT with oestrogen alone is associated with little or no increase in the risk of breast cancer
    • HRT with oestrogen and progestogen can be associated with an increase in the risk of breast cancer, however any increase in risk of breast cancer is related to treatment duration and reduces after stopping HRT.

Ovarian cancer

  • A 2015 meta-analysis of 52 epidemiological studies has shown an increased risk of ovarian cancer with oestrogen-only and combined HRT. While this study provides evidence of an association between HRT use and some tumour subtypes, it provides insufficient evidence to claim that HRT causes ovarian cancer
  • When counselling patients, it is important to discuss these findings in terms of absolute risk
  • With 5 years of HRT use, there could be one additional ovarian cancer per 1000 users and one additional death per 1700 users among women of all ages.

Premature ovarian insufficiency

  • In women with premature ovarian insufficiency (menopause under 40 years) it is important to start hormonal treatment either with HRT or a combined hormonal contraceptive
  • This treatment should be continued until at least the age of natural menopause (unless contraindicated) to protect against the increased risk of dementia, cognitive decline, cardiovascular disease, and osteoporosis seen in these women
  • HRT has a negligible effect on blood pressure and beneficial effects on metabolic parameters, when compared with a combined oral contraceptive
  • Both HRT and combined oral contraceptives offer bone protection
  • HRT is not a contraceptive
  • Consider referring women with premature ovarian insufficiency to healthcare professionals who have the relevant experience to help them manage all aspects of physical and psychosocial health related to their condition.

Review each treatment for menopausal symptoms

  • At 3 months to assess efficacy and tolerability
  • Annually thereafter unless there are clinical indications for an earlier review (such as treatment ineffectiveness, side effects, or adverse effects).

Oestrogens and progestogens

  • Oral oestrogen increases sex hormone binding globulin levels, which can result in lower free testosterone concentrations—a benefit if women are noticing postmenopausal hirsutism
  • Transdermal preparations can be started at a low dose, such as oestradiol 25 mcg patch, or one measure of oestradiol gel and titrated up until symptoms are alleviated. If symptoms are still present after 1 month, an increase to 37.5 mcg, then 50 mcg (patch or gel) is associated with fewer side effects such as breast tenderness and vaginal bleeding, and also keeps risks minimised
  • The increased VTE risk seen with oral preparations is not found using transdermal preparations under 50 mcg oestradiol gel
  • Most women find a standard dose of a 50 mcg patch or two measures of oestradiol gel are adequate for symptom relief; the only exception is younger women either after oophorectomy or with premature ovarian insufficiency who often require higher doses of oestradiol
  • In women who are still experiencing some periods, a cyclical progestogen regime is required in order to regulate the cycles, encouraging a bleed around the end of each month. Cyclical oral formulations contain older progestogens, which protect the endometrium but may have progestogenic side effects
  • For perimenopausal women, micronised progesterone 200 mg a day can be used for 14 days of each month. In women who are more than a year post-last period or have used a cyclical preparation for 2–3 years this can be transferred to a continuous regime using micronised progesterone 100 mg daily, which should keep women amenorrhoeic
  • Micronised progesterone or dydrogesterone should be the first choices of progestogen as they appear to be safer for the cardiovascularsystem, having neutral effect on lipids and coagulation, and a lower risk of breast cancer.

Table 1: Oestrogens and progestogens

Type of progestogen Good forWatch out forPrescribed as

Synthetic: C19 testosterone derivatives    

Norethisterone

Cycle control

Androgenic—good for libido

Some degree of oestrogenic effect caution if VTE risk ++

E2/net fixed combined tablet/patch or as stand alone

Levonorgestrel

As IUS

Cycle control

Low systemic absorption

Excellent contraception

Good for HMB

Androgenic effects (acne, mood)

PMS

52 mg LNG IUS

Or

In combined patch

Synthetic: C21 progesterone derivatives

Medroxyprogesterone acetate

Cycle control

Caution if VTE risk +

SCHRT—E2 plus 10-20 mg cyclically

CCHRT–E2 plus 5 mg conti

Or fixed dose in oral 

Dydrogesterone

Non-androgenic so good if PMS-type side effects

Only available with oral oestrogen

Oral fixed dose

Sequential (including low dose) or combined 

Natural progesterone: Micronised progesterone

Fewer progestogenic side effects

No androgenic or glucocorticoid activity

No impact on lipids

Less effective cycle control

Take at night as may cause sedation

Sequential—200 mg cyclically

Or

Continuous 100 mg daily 

CCHRT=continuous combined hormone replacement therapy; HMB=heavy menstrual bleeding; IUS=intrauterine system; LNG IUS=levonorgestrel-releasing intrauterine system; PMS=premenstrual syndrome; SCHRT=sildenafil citrate hormone replacement therapy; VTE=venous thrombembolism.

Table 2: Progestogens currently licensed for use in the UK as part of combined hormone replacement therapy

Progestogen Oestrogenic Anti-oestrogenicAndrogenicAnti-androgenic GlucocorticoidAnti-mineralocorticoid

Norethisterone

x x x

Levonorgestrel/ norgestrel (including intrauterine devices)

x x x x

Progesterone

x x

Medroxyprogesterone acetate

x x x

Dydrogesterone

x x x

Algorithm 1: Flowchart for hormone replacement therapy prescribing

PCWHF - Flow chart of HRT prescribing

Table 3: Possible medications to use

HRTTablets[A]Second line[A] Transdermal[A]

SEQUENTIAL PREPARATIONS

For patients with:

  • intact uterus
  • perimenopausal-under 1 year or amenorrhoea

Oestradiol 1 mg + norethisterone sequential

Estradiol 2 mg + norethisterone sequential 

Oestradiol + dydrogesterone 1/10 mg sequential

Oestradiol + dydrogesterone 2/10 mg sequential (non-androgenic)

Oestradiol 50 mcg + levonorgestrel 10 mcg patch

Oestradiol 50 mcg + norethisterone 170 mcg patch 

CONTINUOUS COMBINED

Bleed free HRT use if:

  • Over 1 year since last period
  • >54 years
  • >3 years on sequential HRT

Oestradiol 2 mg + norethisterone 1 mg conti

Oestradiol 0.5 mg + dydrogesterone 2.5 mg conti

Oestradiol 1 mg + dydrogesterone 5 mg conti 

Tibolone 2.5 mg

Can be useful if:

  • bloating on oestrogen
  • poor libido
  • endometriosis

Oestradiol 50 mcg + levonorgestrel 7 mcg patch

Oestradiol 50 mcg + norethisterone 170 mcg patch

UNOPPOSED OESTROGEN

Post hysterectomy

Oestradiol 1 mg tablets

Oestradiol 2 mg tablets

 

Oestradiol patch
25 mcg, 37.5 mcg, 50 mcg, 75 mcg, 100 mcg

Oestradiol 0.06% gel


Oestradiol 500 mcg or 1 mg gel sachets

TOPICAL VAGINAL OESTROGEN 

   

Oestradiol 10 mcg vaginal pessaries

Oestriol 0.1% cream

Oestradiol vaginal ring

PROGESTOGEN ADJUNCT TO TOPICAL OESTROGEN IF NO HYSTERECTOMY

Medroxyprogesterone 10 mg d14-28 or 2.5–5 mg daily[B]

Micronised progesterone 200  mg d14-28 or 100 mg daily[B]

Levonorgestrel intrauterine system 52 mg

Replace after five years as per FSRH guidance

 

[A] Use the lowest dose to control symptoms. [B] Day 14-28 (sequential—i.e. still giving periods), daily for continuous combined (bleed-free)

 

 

 

 

 

 

 

 

Full guideline: 

Primary Care Women’s Health Forum. Menopause—guidance on management and prescribing HRT for GPs: based on NICE guidance 2015 and recent updates. September 2020. Available at: pcwhf.co.uk/wp-content/uploads/2021/02/Prescribing-HRT-3.pdf

Published date: September 2017.

Last updated: September 2020.